Surfactant Protein D Levels in GCF Before and After MINST in Periodontitis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCairo University
About this trial
This study will evaluate changes in Surfactant Protein D (SP-D) levels in gingival crevicular fluid (GCF) of patients with periodontitis before and after minimally invasive non-surgical periodontal therapy (MINST).
Participants diagnosed with stage II or III periodontitis will receive minimally invasive non-surgical periodontal treatment. GCF samples will be collected at baseline and 6 months after treatment, and SP-D levels will be measured using enzyme-linked immunosorbent assay (ELISA).
The study will also assess clinical periodontal outcomes, including full-mouth plaque score, full-mouth bleeding score, probing pocket depth, clinical attachment level, gingival recession, and patient satisfaction. Each participant will serve as their own control by comparing baseline values with 6-month post-treatment values.
Eligibility criteria
Qualifiers
Male and female participants aged 18 years or older.
Diagnosis of periodontitis, classified as stage II or stage III according to the 2018 classification system.
Presence of at least one tooth with probing pocket depth (PPD) of 5 mm or more, clinical attachment loss (CAL), and radiographic evidence of bone loss.
Presence of at least one intrabony defect with a radiographic intrabony component measuring 3 mm or more.
Disqualifiers
Current smokers or individuals with a history of smoking within the past year.
Pregnant or lactating women.
Use of systemic antibiotics or anti-inflammatory medications within the last 3 months.
Known allergy to any materials or agents used during periodontal therapy.
Trial design
Treatments tested in this trial
- Minimally Invasive Non-Surgical Periodontal Therapy
Treatment groups
18 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov